Tepeoğlu Merih, Ayva Şebnem, Ok Atılgan Alev, Tunca M Zeyneb, Özdemir B Handan, Moray Gökhan, Yıldırım Sedat, Arslan Gülnaz, Haberal Mehmet
Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey.
Exp Clin Transplant. 2014 Jun;12(3):233-7.
Solid-organ transplant recipients have a high risk of developing nonmelanoma skin cancers. This study sought to determine the incidence of skin cancer and identify possible risk factors for skin cancer in kidney transplant recipients.
Nonmelanoma skin cancer was diagnosed and confirmed with histology in 33 of 1275 kidney transplant recipients (2.6%). Demographic and clinical findings were reviewed retrospectively.
Nonmelanoma skin cancers included squamous cell carcinoma in 10 patients (30%), basal cell carcinoma in 9 patients (27%), Kaposi sarcoma in 9 patients (27%), squamous cell carcinoma in situ in 3 patients (9%), and cutaneous lymphoma in 2 patients (6%). The ratio of squamous cell carcinoma to basal cell carcinoma was 1.1:1. The mean time from transplant to skin cancer diagnosis was 65 ± 55 months (range, 0-180 mo). Immunosuppressive therapy was based on cyclosporine in 22 patients (67%), tacrolimus in 8 patients (24%), and combination therapy (cyclosporine and azathioprine) in 3 patients (9%).
Nonmelanoma skin cancer is an important clinical problem in kidney transplant recipients. Interventions that may benefit kidney transplant recipients may include intensive patient education, protection against sun exposure, and dermatologic screening programs.
实体器官移植受者发生非黑色素瘤皮肤癌的风险很高。本研究旨在确定皮肤癌的发病率，并找出肾移植受者患皮肤癌的可能风险因素。
1275例肾移植受者中有33例（2.6%）经组织学诊断并确诊为非黑色素瘤皮肤癌。对人口统计学和临床结果进行回顾性分析。
非黑色素瘤皮肤癌包括10例（30%）鳞状细胞癌、9例（27%）基底细胞癌、9例（27%）卡波西肉瘤、3例（9%）原位鳞状细胞癌和2例（6%）皮肤淋巴瘤。鳞状细胞癌与基底细胞癌的比例为1.1:1。从移植到皮肤癌诊断的平均时间为65±55个月（范围0 - 180个月）。22例（67%）患者的免疫抑制治疗以环孢素为基础，8例（24%）以他克莫司为基础，3例（9%）采用联合治疗（环孢素和硫唑嘌呤）。
非黑色素瘤皮肤癌是肾移植受者的一个重要临床问题。可能使肾移植受者受益的干预措施包括强化患者教育、防晒和皮肤科筛查项目。
